Researchers analyzed data from 321 patients treated with a double-dose medication for tuberculosis. They looked specifically at how many bacteria were visible under a microscope using auramine and fluorescein stains during the first two weeks of treatment.
The study found that higher amounts of these bacteria at the very beginning of treatment were linked to an unfavorable outcome, such as treatment failure or relapse. Specifically, every 100 extra bacilli per field increased the odds of a poor outcome by about 5 percent.
Because there were only 15 cases of failure or relapse among the 321 patients studied, these results should be viewed with caution. The small number of outcomes makes it difficult to say if this finding can change how doctors treat patients in the first two weeks. Currently, there is no evidence that using these specific counts provides extra value for daily clinical decisions.
Common questions
Can this test help doctors know if a tuberculosis treatment is working?
The study found that counting bacteria at the start of treatment could predict if a patient would later experience a relapse. However, because only 15 out of 321 patients had a failure or relapse, the results are not yet strong enough to change how doctors manage care during the first two weeks.
What did the study find regarding auramine levels?
Researchers found that higher amounts of bacteria seen with auramine staining at the start were linked to worse outcomes. Specifically, for every 100 extra bacilli per field, there was a 5 percent higher chance of treatment failure or relapse.
Is this finding reliable enough to change current medical practice?
The findings should be interpreted with caution because the number of patients who experienced a relapse was small. The study did not find added value for using these specific counts to guide treatment during the first two weeks of care.
